Long-term Temporal Stability of Peripheral Blood DNA Methylation Profiles in Patients With Inflammatory Bowel Disease

被引:9
|
作者
Joustra, Vincent [1 ]
Yim, Andrew Y. F. Li [2 ,3 ]
Hageman, Ishtu [3 ]
Levin, Evgeni [4 ,5 ]
Adams, Alex [6 ]
Satsangi, Jack [6 ]
de Jonge, Wouter J. [3 ]
Henneman, Peter [2 ]
D'Haens, Geert [1 ]
机构
[1] Univ Amsterdam, Dept Gastroenterol & Hepatol, Amsterdam Gastroenterol Endocrinol Metab, Amsterdam UMC, Amsterdam, Netherlands
[2] Univ Amsterdam, Dept Human Genet, Genome Diagnost Lab, Amsterdam UMC, Amsterdam, Netherlands
[3] Univ Amsterdam, Tytgat Inst Liver & Intestinal Res, Amsterdam UMC, Amsterdam, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, Amsterdam, Netherlands
[5] Horaizon BV, Delft, Netherlands
[6] Univ Oxford, Hosp NHS Fdn Trust, John Radcliffe Hosp, NIHR Oxford Biomed Res Ctr,Translat Gastroenterol, Oxford, England
关键词
Biomarkers; Epigenetics; Personalized Medicine; CROHNS-DISEASE; EPIGENETIC ALTERATIONS; IBD; DIAGNOSIS; SUSCEPTIBILITY; PACKAGE; RISK;
D O I
10.1016/j.jcmgh.2022.12.011
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: There is great current interest in the potential application of DNA methylation alterations in peripheral blood leukocytes (PBLs) as biomarkers of susceptibility, progression, and treatment response in inflammatory bowel disease (IBD). However, the intra-individual stability of PBL methylation in IBD has not been characterized. Here, we studied the long-term stability of all probes located on the Illumina HumanMethylation EPIC BeadChip array. METHODS: We followed a cohort of 46 adult patients with IBD (36 Crohn's disease [CD], 10 ulcerative colitis [UC]; median age, 44 years; interquartile range [IQR] 27-56 years; 50% female) that received standard care follow-up at the Amsterdam University Medical Centers. Paired PBL samples were collected at 2 time points with a median of 7 years (range, 2-9 years) in between. Differential methylation and intra-class correlation (ICC) analyses were used to identify time-associated differences and temporally stable CpGs, respectively. RESULTS: Around 60% of all EPIC array loci presented poor intra-individual stability (ICC <0.50); 78.114 (approximate to 9%) showed good (ICC, 0.75-0.89), and 41.274 (approximate to 5%) showed excellent (ICC >= 0.90) stability, between both measured time points. Focusing on previously identified consistently differentially methylated positions indicated that 22 CD-, 11 UC-, and 24 IBD-associated loci demonstrated high stability (ICC >= 0.75) over time; of these, we observed a marked stability of CpG loci associated to the HLA genes. CONCLUSIONS: Our data provide insight into the long-term stability of the PBL DNA methylome within an IBD context,facilitating the selection of biologically relevant and robust IBD-associated epigenetic biomarkers with increased potential for independent validation. These data also have potential implications in understanding disease pathogenesis.
引用
收藏
页码:869 / 885
页数:17
相关论文
共 50 条
  • [41] Long-Term Outcomes of Thalidomide in Refractory Inflammatory Bowel Disease
    Yoon, Jessica
    Gerich, Mark
    Targan, Stephan
    Ippoliti, Andrew
    Vasiliauskas, Eric
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S694 - S695
  • [42] Long-term Outcome of Inflammatory Bowel Disease Unclassified in Children
    Paul, Siba Prosad
    Sandhu, Bhupinder Kaur
    INDIAN PEDIATRICS, 2017, 54 (09) : 742 - 745
  • [43] Long-Term Scheduled Therapy with Infliximab in Inflammatory Bowel Disease
    Armuzzi, Alessandro
    De Vincentis, Fabio
    Marzo, Manuela
    Mocci, Giammarco
    Felice, Carla
    Fedeli, Paolo
    De Vitis, Italo
    Papa, Alfredo
    Gasbarrini, Antonio
    Guidi, Luisa
    GASTROENTEROLOGY, 2009, 136 (05) : A663 - A663
  • [44] Long-term management of anemia in chronic inflammatory bowel disease
    Mickisch, O
    Baniewicz, W
    Lutz-Vorderbrügge, A
    Schreiber, S
    Küppers, B
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2002, 40 (04): : 241 - 248
  • [45] Long-term scheduled therapy with infliximab in inflammatory bowel disease
    Armuzzi, A.
    De Vincentis, F.
    Marzo, M.
    De Pascalis, B.
    Roberto, I.
    Mocci, G.
    Fiore, F.
    Leso, V.
    Fedeli, P.
    Papa, A.
    De Vitis, I.
    Melina, D.
    Fedeli, G.
    Gasbarrini, A.
    Guidi, L.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2009, 13 : 84 - 84
  • [46] Long-Term Efficacy of Vedolizumab in Pediatric Inflammatory Bowel Disease
    Sarles, Harry E., Jr.
    Whitney, Annette E.
    Kuten, Samantha A.
    Van Anglen, Lucinda J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S643 - S644
  • [47] Thioguanine in inflammatory bowel disease: Long-term efficacy and safety
    Ward, Mark G.
    Patel, Kamal V.
    Kariyawasam, Viraj C.
    Goel, Rishi
    Warner, Ben
    Elliott, Tim R.
    Blaker, Paul A.
    Irving, Peter M.
    Marinaki, Anthony M.
    Sanderson, Jeremy D.
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2017, 5 (04) : 563 - 570
  • [48] Long-Term Safety and Efficacy of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease
    Mock, Joseph D.
    Tuskey, Anne G.
    Rubin, Amy
    Behm, Brian W.
    GASTROENTEROLOGY, 2015, 148 (04) : S257 - S257
  • [49] The effect of concomitant ankylosing spondylitis on long-term outcome of patients with inflammatory bowel disease
    Atay, Kadri
    Eyvazov, Hayyam
    Bozcan, Selma
    Eskazan, Tugce
    Demir, Nurhan
    Hatemi, Ibrahim
    Erzin, Yusuf
    Celik, Aykut Ferhat
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2019, 30 (07): : 599 - 604
  • [50] Short and Long-Term Effectiveness of Azathioprine and Mercaptopurine in Patients With Inflammatory Bowel Disease (IBD)
    Castano-Milla, Carlos
    Chaparro, Maria
    Mate, J.
    Gisben, Javier P.
    GASTROENTEROLOGY, 2011, 140 (05) : S592 - S592